Literature DB >> 21177402

Treatment and timing in invasive mould disease.

Johan Maertens1, Andreas H Groll, Catherine Cordonnier, Rafael de la Cámara, Emmanuel Roilides, Oscar Marchetti.   

Abstract

Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use mould-active antifungal agents is much debated. Current approaches to antifungal prophylaxis, early treatment (empirical and pre-emptive therapy) and treatment of documented mould infections in onco-haematology patients are discussed.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21177402     DOI： 10.1093/jac/dkq440

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  16 in total

Review 1.  Treatment principles for the management of mold infections.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

Review 2.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

3.  Toward Electronic Surveillance of Invasive Mold Diseases in Hematology-Oncology Patients: An Expert System Combining Natural Language Processing of Chest Computed Tomography Reports, Microbiology, and Antifungal Drug Data.

Authors:  Michelle R Ananda-Rajah; Christoph Bergmeir; François Petitjean; Monica A Slavin; Karin A Thursky; Geoffrey I Webb
Journal:  JCO Clin Cancer Inform       Date:  2017-11

Review 4.  Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.

Authors:  Matt Shirley; Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

Review 5.  Lichtheimia Infection in a Lymphoma Patient: Case Report and a Brief Review of the Available Diagnostic Tools.

Authors:  Stefan Zimmerli; Ralf Bialek; Igor W Blau; Andreas Christe; Cornelia Lass-Flörl; Elisabeth Presterl
Journal:  Mycopathologia       Date:  2016-04-26       Impact factor: 2.574

Review 6.  Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).

Authors:  Can Boğa; Zahit Bolaman; Seçkin Çağırgan; İhsan Karadoğan; Mehmet Ali Özcan; Fahir Özkalemkaş; Rabin Saba; Mehmet Sönmez; Esin Şenol; Hamdi Akan; Murat Akova
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

7.  Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia.

Authors:  Melinda Paholcsek; Gabor Fidler; Jozsef Konya; Laszlo Rejto; Gabor Mehes; Evelin Bukta; Juergen Loeffler; Sandor Biro
Journal:  BMC Infect Dis       Date:  2015-07-01       Impact factor: 3.090

8.  Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.

Authors:  M Döring; O Blume; S Haufe; U Hartmann; A Kimmig; C-P Schwarze; P Lang; R Handgretinger; I Müller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-31       Impact factor: 3.267

9.  SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients.

Authors:  M T Montagna; G Lovero; C Coretti; D Martinelli; M Delia; O De Giglio; M Caira; F Puntillo; D D'Antonio; M Venditti; V Sambri; F Di Bernardo; A Barbui; G Lo Cascio; E Concia; M Mikulska; C Viscoli; N Maximova; A Candoni; S Oliveri; G Lombardi; L Pitzurra; M Sanguinetti; R Masciari; T Santantonio; S Andreoni; F Barchiesi; P Pecile; C Farina; P Viale; G Specchia; G Caggiano; L Pagano
Journal:  Infection       Date:  2013-10-23       Impact factor: 3.553

Review 10.  Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.

Authors:  Richard C Barton
Journal:  Scientifica (Cairo)       Date:  2013-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.